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Abstract
The clinical burden of the A/H1NI influenza pandemic in the
general population is comparable to those of previous seasonal
influenza epidemics in terms of total numbers of clinical cases. It
is higher in young, and virtually nil in older adults. These asser-
tions can be made safely because of long-established clinical
influenza surveillance systems. However, what characterizes this
pandemic is that it may kill young patients without known risk
factors. Surveillance systems dedicated to the most severely ill
patients admitted to intensive care units have been implemented
only recently. The present experience strongly supports the
view that they should be made perennial.
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The assessment of the severity of the present A/H1N1 pan-
demic implies that mortality and morbidity reference values
are available. During pandemics, and during this very pan-
demic, there is evidence that deaths from primary influenza
virus or bacterial pneumonias occur in patients without
known risk factors. In France, by 8 December, 630 cases
were hospitalized with A/H1N1 and 126 deaths were
reported, among which 20 occurred in patients with no
known risk factor [1]. In general, these patients died with an
acute respiratory distress syndrome (ARDS) and were trea-
ted in intensive care units (ICU). Unfortunately, there was
no established surveillance system for the patients in ICUs
with proven influenza before 2009. The comparison to refer-
ence values of the past is therefore, up to now, impossible.
The situation is different for morbidity. Comparison with
previous seasonal epidemics can be informative. First, it is
expected that the clinical attack rate will be larger during a
pandemic than during a seasonal epidemic, as a larger part of
the population may be susceptible to the new strain of virus.
Second, there are several lines of evidence of pre-existing
immunity against pandemic A/H1N1, particularly in the
elderly population [2,3] suggesting that disease incidence
associated with pandemic A/H1N1 may finally not differ
much from that of seasonal H1N1.
Here we take advantage of the data accrued over more
than 25 years to provide such a comparison. In November
1984, we set up a computerized real-time surveillance of
Influenza Like Illnesses (ILI) and other frequent communica-
ble diseases based on a network of voluntary unpaid sentinel
general practitioners (SGP)[4]. The case definition of ILI has
remained unchanged since 1984: ‘sudden fever of more than
39C, myalgias, respiratory signs’. During the 1984–1999
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period, the SGPs used home terminals, and after 2000 they
used the Internet to report the cases. Electronic bulletins
provide an immediate return of information. Since 1995,
these bulletins are posted on the public WEB. The database
of weekly national and regional standardized all-age inci-
dences can be freely downloaded. [5]
The present results (Fig. 1) show the similarities and
peculiarities of the time course of the incidence of ILI
during the current A/H1N1 pandemic, up to the week end-
ing on 6 December 2009. This time course has little chance
to have been modified by the ongoing mass vaccination
campaign as it was launched only recently: up to 4
December 2009 c. 1,5 million people were vaccinated, of a
total of 66 million. The only remarkable event occurred in
FIG. 2. Comparison of the H1N1v pandemic (red) with the three closest epidemics of seasonal flu during the period 1984–2009 in France up
to the last week of 2009.
FIG. 1. Comparison of the H1N1v pandemic (red curve) with the
24 previous seasonal epidemics observed in France between 1984
and 2009 up to the last week of 2009.
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 389–399
394 Clinical Microbiology and Infection, Volume 16 Number 4, April 2010 CMI
September and October 2009 where a significant number of
ILI patients presented to their GP, while there was almost
none at that time of the year during the past 24 previous
seasonal epidemics [6].
Figure 2 shows the analysis, by age class, of the present
pandemic. Two specific epidemiological patterns emerged: in
the 0–5 years and 5–18 age groups, the observed incidence
exceeded all past epidemic levels. Up to week 47 they paral-
leled three past seasonal epidemics, those of 1993 and 2003
during which the main circulating virus was H3N2, and that
of 1988 during which the main circulating virus was H1N1.
The other remarkable pattern concerns those older than 50
years where the observed incidence was almost nil, in sharp
contrast with all that has been observed previously in sea-
sonal epidemics. This clearly indicates that the present ‘new’
strain of H1N1 was not that new to those older than
50 years, or at least that important cross-protective immuni-
zations occurred.
The comparative examination of the patterns observed in
all age classes indicates that the clinical attack rate of this
A/H1N1 pandemic agent is likely to be eventually much
smaller than it was with the H1N1 seasonal virus in 1988,
which happened to be the largest ever observed by the Sen-
tinel Network, and that it will likely be comparable to many
other epidemics in the French influenza catalogue. The
future, which is largely unpredictable, will definitely tell if
this view has to be changed, for example because of sec-
ondary waves. It must also be stressed that the present sur-
veillance gives only information on the symptomatic
influenza, while it is known that in all seasonal epidemics
there is a noticeable proportion of infected (and infectious)
subjects who are asymptomatic and infectious [7], and that
in the current A/H1N1 epidemic this proportion might even
be larger [8].
There is a paradox in terms of epidemiological surveil-
lance: the present pattern of clinical influenza can be safely
compared with the previous seasonal patterns, as a long-
established effort has been maintained to ensure year after
year a reliable information system. However, this comparison
does not characterize the present epidemic as remarkable.
On the other hand, it is strongly felt that the very character-
istic of the present epidemic which can qualify it as being
truly a pandemic is the number of young patients without
known risk factors requiring admission to intensive care and
suffering a fatal outcome. However, this assertion is not sup-
ported by real data from the past.
New surveillance systems, with precise case definitions
and modern data monitoring, have been devised this year
in France and other countries to monitor closely the hos-
pitalised cases of severe influenza during this pandemic [9].
It will be important not to discontinue this effort when
this pandemic is over. The collection of such data – which
provide the reference values – will be invaluable in the
long term, when a new pandemic will inevitably occur. It
must indeed be stressed that the range of interpandemic
periods observed during the 11 previous influenza pandem-
ics since 1729 [10] was 8 (observed between 1782 and
1789) to 42 years (observed between 1847 and 1889, i.e.
only one year less than the 42 between 2009 and 1968).
Finally, the public must be aware that the rationale for the
mass vaccination campaign against A/H1N1 is to avoid the
severe cases that are most likely specific to the pandemic
and that these cases can occur even when the clinical
attack rate is comparable to the past seasonal epidemics, as
is the case presently.
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Abstract
Nucleotide sequences of genes conferring isoniazid resistance
(katG, inhA, oxyR–ahpC and ndh) and ethionamide resistance
(ethA) in 160 drug-resistant Mycobacterium tuberculosis clinical iso-
lates from Thailand were analysed. Mutations in the katG gene
were found in 129 isolates, predominantly at codon 315, which
was mutated in 127 isolates. Twenty-two isolates had mutations
in the inhA promoter and coding region. Mutations in the oxyR–
ahpC intergenic region and in ndh were detected in four and
one isolate(s), respectively. Of 24 ethionamide-resistant isolates,
13 had mutations in the ethA gene. However, these mutations
were dispersed along the entire gene, with no codon predomi-
nating significantly.
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Phenotypic methods of antituberculous drug susceptibility
testing are time-consuming, requiring at least 7–10 days using
automated culture systems and up to 6 weeks by
conventional methods. Much effort has been spent on
reducing the time needed to identify drug-resistant strains.
Several genotypic methods based on detection of mutations
conferring drug resistance have been developed and used as
rapid methods for identification of drug resistance.
Resistance to isoniazid (INH) is associated with a variety
of genes, including katG, inhA, ahpC, kasA and ndh [1–4].
Mutation of the katG codon 315 has been shown to be the
most common mechanism of INH resistance [5–7]. Ethiona-
mide (ETH) is one of the most frequently used effective sec-
ond-line drugs. The monooxygenase enzyme encoded by the
ethA gene has recently been identified and found to be capa-
ble of converting ETH to an active form. Alterations in ethA
confer ETH resistance [8,9]. However, there is limited infor-
mation on the occurrence of ethA mutations in ETH-resistant
Mycobacterium tuberculosis clinical isolates. In particular, there
have been no studies on ETH-resistant isolates in Thailand.
This study aims to characterize the type and frequency of
mutations conferring INH and ETH resistance in drug-resis-
tant M. tuberculosis clinical isolates from Thailand.
Overall, 170 isolates (one isolate/patient) comprising 160
INH-resistant and 10 INH-susceptible isolates were ran-
domly selected from the Molecular Mycology and Mycobac-
teriology Laboratory, Drug Resistant Tuberculosis Research
Fund during 2005–2006. Mycobacteria were cultured on
Lo¨wenstein–Jensen medium and incubated at 37C for 3–4
weeks. The susceptibility testing was performed using the
standard disc elution method [10]. All INH-resistant and
ETH-resistant isolates were resistant to ‡1 lg/mL of INH
and ‡5 lg/mL of ETH, respectively.
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